Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Drug Benefit May Give Marginal Boost To Sanofi’s Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

Although Plavix sales are up, the company has not seen any improvement in its other products for the elderly, Lantus and Actonel.

You may also be interested in...

Bristol/Sanofi Seek Settlement In Plavix Case

In an unexpected twist, the companies offer Apotex an additional eight months of exclusivity in the proposed settlement.

Acomplia Is "Not Approvable" For Smoking Cessation, "Approvable" For Weight Loss

FDA issued a split decision for Sanofi-Aventis' rimonabant NDAs.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts